Levetiracetam is the drug of choice for focal (partial) onset seizures.
Current clinical practice and guidelines (including ILAE and NICE) prefer Levetiracetam (or Lamotrigine) as a first-line monotherapy due to its broad-spectrum efficacy, rapid onset, linear pharmacokinetics, minimal drug interactions, and superior safety profile compared to older agents.
Breakdown of the options:
Levetiracetam: First-line drug of choice for newly diagnosed focal seizures (both with and without focal-to-bilateral tonic-clonic evolution).
Phenytoin: Classic first-line agent for focal seizures, but largely replaced by newer anticonvulsants due to zero-order kinetics, severe drug-drug interactions, and adverse effects (e.g., gingival enlargement, nystagmus, ataxia).
Gabapentin: Used primarily as adjunctive (add-on) therapy for focal seizures, or for neuropathic pain.
Lorazepam: First-line drug of choice for acute emergency management of status epilepticus, not long-term monotherapy.


